Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Akira Fukutomi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5004637658. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
112
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 28

  1. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  3. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  4. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… Co-author DOI 10.1002/cnr2.1507↗
  5. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2021.08.009↗
  6. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  7. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  8. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  9. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  10. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Last author DOI 10.1016/j.pan.2020.07.006↗
  11. FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the … Last author DOI 10.1097/mpa.0000000000001692↗
  12. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  13. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer. Co-author DOI 10.1002/bjs.11328↗
  14. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japa… Last author DOI 10.1016/j.pan.2019.01.001↗
  15. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Last author DOI 10.1111/cas.13883↗
  16. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Last author DOI 10.18632/oncotarget.26633↗
  17. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  18. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … First author DOI 10.1016/j.pan.2018.07.007↗
  19. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Last author DOI 10.1097/mpa.0000000000001049↗
  20. Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer. First author DOI 10.1016/j.pan.2017.09.011↗
  21. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Co-author DOI 10.1016/s0140-6736(16)30583-9↗
  22. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv603↗
  23. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  24. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  25. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Co-author DOI 10.1111/cas.12709↗
  26. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor ty… Co-author DOI 10.1093/jjco/hyu034↗
  27. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1111/cas.12501↗
  28. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuhiko Uesaka · 10 shared papers, 2016–2026 · strength 1.29
  2. Narikazu Boku · 12 shared papers, 2013–2026 · strength 1.09
  3. Akiko Todaka · 11 shared papers, 2017–2021 · strength 0.96
  4. Soichiro Morinaga · 8 shared papers, 2016–2026 · strength 0.88
  5. Hirochika Toyama · 5 shared papers, 2020–2026 · strength 0.87
  6. Yukiyasu Okamura · 8 shared papers, 2016–2026 · strength 0.85
  7. Nobumasa Mizuno · 11 shared papers, 2015–2021 · strength 0.85
  8. Shoji Nakamori · 11 shared papers, 2015–2022 · strength 0.84
  9. Takuji Okusaka · 11 shared papers, 2013–2021 · strength 0.66
  10. Masafumi Ikeda · 10 shared papers, 2013–2021 · strength 0.56
  11. Masato Ozaka · 7 shared papers, 2018–2021 · strength 0.56
  12. Hideki Ueno · 8 shared papers, 2013–2021 · strength 0.55
  13. Tatsuya Ioka · 8 shared papers, 2013–2021 · strength 0.54
  14. Junji Furuse · 8 shared papers, 2013–2021 · strength 0.54
  15. Teiichi Sugiura · 5 shared papers, 2017–2023 · strength 0.52
  16. Naoto Gotohda · 2 shared papers, 2026 · strength 0.52
  17. Naohiro Sata · 6 shared papers, 2016–2022 · strength 0.50
  18. Satoshi Kobayashi · 6 shared papers, 2018–2021 · strength 0.50
  19. Makoto Ueno · 5 shared papers, 2018–2021 · strength 0.45
  20. Amane Takahashi · 3 shared papers, 2020–2026 · strength 0.43
  21. Keiko Kamei · 5 shared papers, 2018–2020 · strength 0.41
  22. Hiroshi Ishii · 5 shared papers, 2015–2021 · strength 0.34
  23. Atsuyuki Maeda · 2 shared papers, 2022–2026 · strength 0.34
  24. Ippei Matsumoto · 4 shared papers, 2016–2023 · strength 0.34
  25. Satoshi Hirano · 4 shared papers, 2016–2023 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.